|
1
|
Hildebrandt MA, Gu J and Wu X:
Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert
Opin Drug Metab Toxicol. 5:745–755. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zornosa C, Vandergrift JL, Kalemkerian GP,
Ettinger DS, Rabin MS, Reid M, Otterson GA, Koczywas M, D'Amico TA,
Niland JC, et al: First-line systemic therapy practice patterns and
concordance with NCCN guidelines for patients diagnosed with
metastatic NSCLC treated at NCCN institutions. J Natl Compr Canc
Netw. 10:847–856. 2012.PubMed/NCBI
|
|
4
|
Ivy KD and Kaplan JH: A re-evaluation of
the role of hcTR1, the human high-affinity copper transporter, in
platinum-drug entry into human cells. Mol Pharmacol. 83:1237–1246.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Choi MK and Kim DD: Platinum transporters
and drug resistance. Arch Pharm Res. 29:1067–1073. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fisher MD and D'Orazio A: Phase II and III
trials: Comparison of four chemotherapy regimens in advanced non
small-cell lung cancer (ECOG 1594). Clin Lung Cancer. 2:21–22.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schiller JH, Harrington D, Belani CP, et
al: Comparison of four chemotherapy regimens for advanced
non-small-cell lung cancer. N Engl J Med. 346:92–98. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fossella F, Pereira JR, von Pawel J, et
al: Randomized, multinational, phase III study of docetaxel plus
platinum combinations versus vinorelbine plus cisplatin for
advanced non-small-cell lung cancer: The tax 326 study group. J
Clin Oncol. 21:3016–3024. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu JJ, Lu J and McKeage MJ: Membrane
transporters as determinants of the pharmacology of platinum
anticancer drugs. Curr Cancer Drug Targets. 12:962–986. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mellor HR and Callaghan R: Resistance to
chemotherapy in cancer: A complex and integrated cellular response.
Pharmacology. 81:275–300. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zisowsky J, Koegel S, Leyers S, et al:
Relevance of drug uptake and efflux for cisplatin sensitivity of
tumor cells. Biochem Pharmacol. 73:298–307. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gupta A and Lutsenko S: Human copper
transporters: Mechanism, role in human diseases and therapeutic
potential. Future Med Chem. 1:1125–1142. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kuo MT, Chen HH, Song IS, Savaraj N and
Ishikawa T: The roles of copper transporters in cisplatin
resistance. Cancer Metastasis Rev. 26:71–83. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Steiger D, Fetchko M, Vardanyan A,
Atanesyan L, Steiner K, Turski ML, Thiele DJ, Georgiev O and
Schaffner W: The drosophila copper transporter ctr1C functions in
male fertility. J Biol Chem. 285:17089–17097. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liang ZD, Long Y, Tsai WB, et al:
Mechanistic basis for overcoming platinum resistance using copper
chelating agents. Mol Cancer Ther. 11:2483–2494. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen HH, Yan JJ, Chen WC, et al:
Predictive and prognostic value of human copper transporter 1
(hctr1) in patients with stage III non-small-cell lung cancer
receiving first-line platinum-based doublet chemotherapy. Lung
Cancer. 75:228–234. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Taylor PT and Haverstick D: Re: New
guidelines to evaluate the response to treatment in solid tumors
(ovarian cancer). J Natl Cancer Inst. 97:1512005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Holzer AK, Varki NM, Le QT, Gibson MA,
Naredi P and Howell SB: Expression of the human copper influx
transporter 1 in normal and malignant human tissues. J Histochem
Cytochem. 54:1041–1049. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nakagawa T, Inoue Y, Kodama H, Yamazaki H,
Kawai K, Suemizu H, Masuda R, Iwazaki M, Yamada S, Ueyama Y, et al:
Expression of copper-transporting p-type adenosine triphosphatase
(ATP7B) correlates with cisplatin resistance in human non-small
cell lung cancer xenografts. Oncol Rep. 20:265–270. 2008.PubMed/NCBI
|
|
20
|
Konstantakou EG, Voutsinas GE, Karkoulis
PK, Aravantinos G, Margaritis LH and Stravopodis DJ: Human bladder
cancer cells undergo cisplatin-induced apoptosis that is associated
with p53-dependent and p53-independent responses. Int J Oncol.
5:401–416. 2009.
|
|
21
|
Köberle B, Tomicic MT, Usanova S and Kaina
B: Cisplatin resistance: Preclinical findings and clinical
implications. Biochim Biophys Acta. 1806:172–182. 2010.PubMed/NCBI
|
|
22
|
Abada P and Howell SB: Regulation of
cisplatin cytotoxicity by cu influx transporters. Metal Based
Drugs. 2010:3175812010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lenartowicz M and Krzeptowski W: Structure
and function of ATP7A and ATP7B proteins-Cu-transporting ATPases.
Postepy Biochem. 56:317–327. 2010.PubMed/NCBI
|
|
24
|
Zhou B and Gitschier J: Hctr1: A human
gene for copper uptake identified by complementation in yeast. Proc
Natl Acad Sci USA. 94:7481–7486. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cox DW and Moore SD: Copper transporting
p-type atpases and human disease. J Bioenerg Biomembr. 34:333–338.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Howell SB, Safaei R, Larson CA and Sailor
MJ: Copper transporters and the cellular pharmacology of the
platinum-containing cancer drugs. Mol Pharmacol. 77:887–894. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang Y, Li M, Yao Q and Chen C: Roles and
mechanisms of copper transporting atpases in cancer pathogenesis.
Med Sci Monit. 15:RA1–RA5. 2009.PubMed/NCBI
|
|
28
|
Furukawa T, Komatsu M, Ikeda R, Tsujikawa
K and Akiyama S: Copper transport systems are involved in multidrug
resistance and drug transport. Curr Med Chem. 15:3268–3278. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li ZH, Qiu MZ, Zeng ZL, Luo HY, Wu WJ,
Wang F, Wang ZQ, Zhang DS, Li YH and Xu RH: Copper-transporting
p-type adenosine triphosphatase (ATP7A) is associated with
platinum-resistance in non-small cell lung cancer (NSCLC). J Transl
Med. 10:212012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Inoue Y, Matsumoto H, Yamada S, Kawai K,
Suemizu H, Gika M, Takanami I, Iwazaki M and Nakamura M:
Association of ATP7A expression and in vitro sensitivity to
cisplatin in non-small cell lung cancer. Oncol Lett. 1:837–840.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mangala LS, Zuzel V, Schmandt R, Leshane
ES, Halder JB, ArmaizPena GN, Spannuth WA, Tanaka T, Shahzad MM,
Lin YG, et al: Therapeutic targeting of ATP7B in ovarian carcinoma.
Clin Cancer Res. 15:3770–3780. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nakayama K, Kanzaki A, Terada K, Mutoh M,
Ogawa K, Sugiyama T, Takenoshita S, Itoh K, Yaegashi N, Miyazaki K,
et al: Prognostic value of the Cu-transporting ATPase in ovarian
carcinoma patients receiving cisplatin-based chemotherapy. Clin
Cancer Res. 10:2804–2811. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yoshida H, Teramae M, Yamauchi M, Fukuda
T, Yasui T, Sumi T, Honda K and Ishiko O: Association of copper
transporter expression with platinum resistance in epithelial
ovarian cancer. Anticancer Res. 33:1409–1414. 2013.PubMed/NCBI
|
|
34
|
Ishida S, McCormick F, SmithMcCune K and
Hanahan D: Enhancing tumor-specific uptake of the anticancer drug
cisplatin with a copper chelator. Cancer Cell. 17:574–583. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ogane N, Yasuda M, Kameda Y, Yokose T,
Kato H, Itoh A, Nishino S, Hashimoto Y and Kamoshida S: Prognostic
value of organic anion transporting polypeptide 1B3 and copper
transporter 1 expression in endometrial cancer patients treated
with paclitaxel and carboplatin. Biomed Res. 34:143–151. 2013.
View Article : Google Scholar : PubMed/NCBI
|
